Thymosin Beta-4
Also referenced as: Tbeta4, Tβ4
A full-length 43-amino-acid actin-binding peptide investigated in repair biology.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Investigational
Not FDA-approved for the research uses discussed; no established clinical enhancement indication.
- Human data
- Limited
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A full-length 43-amino-acid actin-binding peptide investigated in repair biology.
Not FDA-approved for the research uses discussed; no established clinical enhancement indication.
Full-length thymosin beta-4 should not be automatically equated with every product labeled TB-500, whose identity can vary.
Why It's Being Studied
- Ophthalmic repair research
- Wound research
- Cell migration
Mechanism of Action
Actin binding and cell-migration-related signalling connect it to tissue responses, but these are not proof of improved healing from systemic administration.
Actin binding and cell-migration-related signalling connect it to tissue responses, but these are not proof of improved healing from systemic administration. Full-length thymosin beta-4 should not be automatically equated with every product labeled TB-500, whose identity can vary.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Ophthalmic repair research
- Wound research
- Cell migration
- Ophthalmic clinical research
- Topical wound research
Evidence Summary
Formulation-specific ophthalmic and wound trials exist; they do not validate commercial systemic recovery injections.
Higher tiers carry more weight. Filled tiers have evidence for Thymosin Beta-4; tap to read it.
- Formulation-specific ophthalmic and wound trials exist; they do not validate commercial systemic recovery injections.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Formulation-specific ophthalmic and wound trials exist; they do not validate commercial systemic recovery injections.
Reported Adverse Events in Research
- Long-term systemic safety, product identity and treatment efficacy remain unestablished.
Limitations of Current Evidence
- Full-length thymosin beta-4 should not be automatically equated with every product labeled TB-500, whose identity can vary.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Thymosin Beta-4 | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Limited | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Ophthalmic clinical research, Topical wound research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Thymosin Beta-4 — regulatory document